MarginsXMarginsX
Home › Markets › Health Care › RXRX

Recursion Pharmaceuticals Inc. (RXRX)

RXRX trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$2.90
-8.79% on the day
Market cap
$1.8B
Small cap
Revenue · 2025
$74.7M
+26.9% on 2024
Net income · 2025
-$644.8M
-863.4% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1601830/000160183026000039/0001601830-26-000039-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerRXRX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2021
SEC CIK0001601830
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials · 2025

LineValue
Revenue$74.7M
Net income-$644.8M
Operating income-$648.1M
Net margin-863.4%
Operating margin-867.9%
Revenue growth+26.9%
Cash$743.3M
Total assets$1.5B
P/E (computed)Net income was not positive
P/S (computed)24.2×

Warning signs

Cash runway
21.2 months
$549.9M cash at September 30, 2026
Share count, 1 year
No year-earlier count
Going-concern doubt
No
10-Q filed November 2, 2026
Insider net buying, 12 months
-$8.5M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-02
Cash and burn$549.9M cash; operating cash flow -$77.6M a quarter.Report 2026-09-30
Shares outstanding622,759,259 (2026-10-26).Cover page 2026-10-26
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the marketLatest 2026-10-15
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers LLP, Seattle, Washington, United StatesPCAOB Form AP 2026-03-18
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $8.5M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$18.6M-$119.0M-$77.4M$549.9M$11.9M$68.2M10-Q 2026-11-02
Q2 2026
2026-06-30
$7.7M-$131.0M-$105.9M$545.7M$14.2M$54.9M10-Q 2026-08-05
Q1 2026
2026-03-31
$6.5M-$117.5M-$81.1M$654.5M$16.4M$66.4M10-Q 2026-05-06
Q4 2025
2025-12-31
$35.5M-$108.1M-$46.1M$743.3M$18.7M$74.7M10-K 2026-02-25
Q3 2025
2025-09-30
$5.2M-$162.3M-$117.4M$659.8M$20.8M$43.7M10-Q 2026-11-02
Q2 2025
2025-06-30
$19.2M-$171.9M-$76.4M$525.1M$22.9M$64.6M10-Q 2026-08-05
Q1 2025
2025-03-31
$14.7M-$202.5M-$132.0M$500.5M$25.0M$59.8M10-Q 2026-05-06
Q4 2024
2024-12-31
$4.5M-$178.9M-$115.4M$594.4M$27.4M$58.8M10-K 2026-02-25

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-10-15
Latest annual report10-K2026-02-25
Latest quarterly / interim10-Q2026-11-02
Latest current report8-K2026-11-02
Latest proxyDEFA14A2026-04-30

Source: SEC EDGAR submissions feed, 993 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-9.5%
1 month-16.9%
3 months-3.8%
Year to date-22.1%
1 year-26.4%
From 52-week high-35.8%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
COAGHemab Therapeutics Holdings Inc.$39.05-4.42%$1.8B
MAZEMaze Therapeutics Inc.$33.90-1.25%$1.9B
WWBWindward Bio Group AG Common Shares$30.04+5.40%$1.7B
ALVOAlvotech$4.41+5.13%$1.7B
BCRXBioCryst Pharmaceuticals Inc.$7.45-2.10%$1.9B
VIRVir Biotechnology Inc.$9.58-3.82%$1.6B
MESOMesoblast Limited$12.45-6.18%$1.6B
REPLReplimune Group Inc.$21.41-2.19%$2.0B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier